Outlook Therapeutics, Inc. (OTLK): Price and Financial Metrics
OTLK Price/Volume Stats
| Current price | $8.17 | 52-week high | $40.60 |
| Prev. close | $8.29 | 52-week low | $4.00 |
| Day low | $8.00 | Volume | 271,700 |
| Day high | $8.63 | Avg. volume | 547,081 |
| 50-day MA | $8.53 | Dividend yield | N/A |
| 200-day MA | $12.43 | Market Cap | 106.32M |
OTLK Stock Price Chart Interactive Chart >
Outlook Therapeutics, Inc. (OTLK) Company Bio
Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company engages in identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics. Outlook Therapeutics focuses on monoclonal antibodies in the disease areas of immunology and oncology aspects. Outlook Therapeutics offers its services in the United States.
Latest OTLK News From Around the Web
Below are the latest news stories about OUTLOOK THERAPEUTICS INC that investors may wish to consider to help them evaluate OTLK as an investment opportunity.
OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023Outlook Therapeutics just reported results for the fourth quarter of 2023. |
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUCommencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application (MAA) decision date anticipated in the first half of 2024 Resubmission of the ONS-5010 Biologics License Application (BLA) expected by the end of calendar year 2024 ISELIN, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achiev |
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NORSE EIGHT study on track to commence in Q1 2024Resubmission of ONS-5010 Biologics License Application (BLA) in the U.S. expected by the end of calendar year 2024 ISELIN, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that, following receipt of written confirmation of the NORSE EIGHT proposed cl |
Outlook Therapeutics® Announces Strategic Organizational RealignmentRealignment focused on supporting ONS-5010 U.S. and EU regulatory and commercial prioritiesContinued progress toward commencement of additional adequate and well-controlled study to support the ONS-5010 Biologics License Application (BLA) in the U.S. European regulatory efforts and commercial strategy development continue to advance toward expected approval of ONS-5010 in Europe in the first half of 2024 ISELIN, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a |
Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-TermWith the business potentially at an important milestone, we thought we'd take a closer look at Outlook Therapeutics... |
OTLK Price Returns
| 1-mo | 16.05% |
| 3-mo | 17.05% |
| 6-mo | -11.77% |
| 1-year | -65.09% |
| 3-year | -80.27% |
| 5-year | -74.31% |
| YTD | 3.68% |
| 2023 | -63.52% |
| 2022 | -20.59% |
| 2021 | 4.62% |
| 2020 | 120.34% |
| 2019 | -85.25% |
Continue Researching OTLK
Here are a few links from around the web to help you further your research on Outlook Therapeutics Inc's stock as an investment opportunity:Outlook Therapeutics Inc (OTLK) Stock Price | Nasdaq
Outlook Therapeutics Inc (OTLK) Stock Quote, History and News - Yahoo Finance
Outlook Therapeutics Inc (OTLK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...